Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study by Livshits, Gregory et al.
ARTHRITIS & RHEUMATISM
Vol. 60, No. 7, July 2009, pp 2037–2045
DOI 10.1002/art.24598
© 2009, American College of Rheumatology
Interleukin-6 Is a Significant Predictor of
Radiographic Knee Osteoarthritis
The Chingford Study
Gregory Livshits,
1 Guangju Zhai,
2 Deborah J. Hart,
2 Bernet S. Kato,
2 Huizhong Wang,
3
Frances M. K. Williams,
2 and Tim D. Spector
2
Objective. There is a great need for identification
of biomarkers that could improve the prediction of early
osteoarthritis (OA). We undertook this study to deter-
mine whether circulating levels of interleukin-6 (IL-6),
tumor necrosis factor  (TNF), and C-reactive protein
(CRP) can serve as useful markers of radiographic knee
OA (RKOA) in a normal human population.
Methods. RKOA data were obtained from the
cohort of the Chingford Study, a prospective
population-based study of healthy, middle-aged British
women. The RKOA-affected status of the subjects was
assessed using the Kellgren/Lawrence (K/L) grade as
determined on radiographs obtained at baseline (n 
908) and at 10 years and 15 years thereafter. Serum
levels of CRP, IL-6, and TNF were assayed at 5, 8, and
15 years, using high-sensitivity commercial assays. A
K/L grade of >2 in either knee was used as the outcome
measure. Statistical analyses included analysis of vari-
ance for repeated measurements and logistic regression
models, together with longitudinal modeling of dichot-
omous responses.
Results. During 15 years of followup, the preva-
lence of RKOA (K/L grade >2) increased from 14.7% to
48.7% (P < 0.00001 versus baseline). The body mass
index (BMI) and circulating levels of CRP and IL-6
were consistently and significantly higher in subjects
diagnosed as having RKOA. When multiple logistic
regression was applied to the data, the variables of older
age (P  3.93  10
5), higher BMI at baseline (P 
0.0003), and increased levels of IL-6 at year 5 (P 
0.0129) were determined to be independent predictors of
the appearance of RKOA at year 10. The results were
fully confirmed using longitudinal modeling of repeated
measurements of the data obtained at 3 visits. The odds
ratio for RKOA in subjects whose IL-6 levels were in the
fourth quartile of increasing levels (versus the first
quartile) was 2.74 (95% confidence interval 1.94–3.87).
Conclusion. This followup study showed that in-
dividuals were more likely to be diagnosed as having
RKOA if they had a higher BMI and increased circu-
lating levels of IL-6. These results should stimulate
more work on IL-6 as a potential therapeutic target.
Osteoarthritis (OA) is the most common form of
arthritis and can result in substantial morbidity and
disability in the elderly (1). It is known that OA imposes
a great economic burden on modern society (2,3). Risk
assessment or diagnosis at the early stages of the disease,
coupled with the development of preventive or thera-
peutic interventions, could substantially improve the
quality of life for the elderly and reduce health care
costs. The development of preventive strategies and
early-stage interventions for OA is likely to depend on
identification of the biologic mechanisms and biomark-
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2037ers that underlie progressive deterioration of joint struc-
ture and function. However, there are still no commonly
accepted and reliable biomarkers for predicting the
development and progression of OA and for distinguish-
ing mild, age-related disease from the rarer form of
aggressive, rapidly progressive disease.
Since OA is a heterogeneous and multifactorial
process of joint degeneration, various mechanisms may
be involved in its development. Inflammation is poten-
tially a key mechanism that appears to act through
alteration of cytokine profiles, which occurs secondary
to aging of the immune system or obesity (4–7).
Interleukin-1 (IL-1) and tumor necrosis factor 
(TNF) are of special interest in the elderly, because
both cytokines induce production of IL-6 and because
they have profound effects on body metabolism, body
composition, and the acute-phase response (8–10), all of
which are altered with increasing age. TNF has been
shown to regulate energy expenditure in humans during
inflammation and is associated with low lean body mass,
which is an important marker of physiologic status and a
major predictor of survival, strength, and functional
status in the elderly (11).
The role of IL-6 in inflammation differs from that
of TNF. The levels of IL-6 are elevated in a variety of
inflammatory conditions (12) and in bone resorption
(13). However, IL-6 does not cause symptoms of inflam-
mation when infused at high doses, but rather it sup-
presses the synthesis of other inflammatory cytokines
(14) and causes hepatic production of acute-phase pro-
teins such as C-reactive protein (CRP). Increased circu-
lating levels of CRP and IL-6 have been found to be
predictors of reduced physical mobility (15) and incident
mobility limitation (4) in the elderly. Moreover, there is
a growing body of evidence, obtained mostly from
cross-sectional studies, suggesting that their levels, espe-
cially those of CRP, are elevated in OA (16–18), al-
though results in recent reports have been contradictory
(19). To the best of our knowledge, the contribution of
inflammatory factors such as IL-6 and TNF to the
severity and incidence of OA has not been examined
systematically; in particular, the course of these factors
longitudinally over multiple time points has yet to be
defined.
The major aim of this study was to explore
whether the circulating levels of 3 key inflammation
markers, CRP, IL-6, and TNF, are independently
associated with radiographic knee OA (RKOA) in a
large cohort of middle-aged European women who were
followed up for 15 years. We were also interested in
determining whether the effect of these markers is
independent of the body mass index (BMI), a known
significant predictor of OA (e.g., see ref. 19).
PATIENTS AND METHODS
Study cohort. The participants of this study were white
women, and the data for this cohort were collected within the
framework of the Chingford Study. This is a well-established,
prospective population-based study of middle-aged British
women who have been evaluated intensively for OA and
osteoporosis since 1989. The cohort originally consisted of
1,003 women ages 45–64 years, selected through general
practitioner records. All subjects were recruited from a sample
of 1,353 women as part of a health trial; to avoid selection bias,
the subjects were not aware of the research into OA. There
were no inclusion/exclusion criteria other than age. The cohort
has been followed up biannually, and many clinical, anthropo-
metric, psychosocial, radiologic, and metabolic variables have
been recorded on at least 2 time points (20,21). The Chingford
Study is currently approaching its twentieth year and has
retained 65% of the cohort, with a current age range of
60–82 years. All subjects still participating in the Chingford
Study were reexamined for the present study in Chingford
Hospital in North-East London.
The radiologic and biochemical factors relevant to the
present study included RKOA status obtained from radio-
graphs of both knees, and the serum concentrations of 3
inflammatory cytokines, namely, CRP, IL-6, and TNF. The
radiologic examinations were carried out at year 1 (entry
examination [baseline]) and at year 10 and year 15 thereafter.
Blood samples were obtained at years 5, 8, and 15. Anthropo-
metric assessments, including determination of the BMI, were
carried out at all visits. Table 1 provides details of the study
sample for each variable and at each time point during the 15
years of followup.
Identification of RKOA. Anteroposterior extended-
view weight-bearing radiographs of the knees were obtained at
baseline and at 10 years and 15 years thereafter. Views were
standardized for position, with the backs of the knees in
contact with the cassette, the patella centralized over the lower
end of the femur, and the beam centered 2.5 cm below the
apex of the patella, with a tube-to-film distance of 100 cm.
Radiographs were read by examiners (DJH and TDS) who
were blinded to the clinical information, with the readings
checked against an atlas of radiographic features to determine
a global Kellgren/Lawrence (K/L) grade of RKOA (scale 0–4)
(22) and to evaluate individual features of osteophytes and
joint space narrowing (scale 0–3 for both).
A case of RKOA was defined as a K/L grade of 2i n
either knee. Pairs of knee films were read by a single investi-
gator (DJH or TDS). Reproducibility of this method showed
that intraobserver agreement for side-by-side readings was
high (  0.88), and reproducibility for detecting change in
longitudinal radiographs was also relatively high (  0.79).
We found little difference in the reproducibility between
blinded readings (intraobserver   0.83, longitudinal  
0.70) and side-by-side readings, so the main radiographic
analysis was performed with baseline and followup films read
side-by-side. In the statistical analysis, we examined the asso-
ciation of the predictor variables with a dichotomous variable
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viduals, with 1 indicating affected (i.e., K/L grade 2) and 0
indicating unaffected (i.e., K/L grade 2).
Measurement of cytokine levels. Since blood samples
were not available for the entire cohort, some data on cytokine
levels were missing; the corresponding sample sizes for each
variable are given in Table 1. After subjects fasted overnight,
blood samples were obtained by venepuncture, and the cells
were removed by centrifugation. Serum aliquots were stored at
70°C until analyzed. Serum CRP levels were determined with
a high-sensitivity nephelometric method using the Beckman
Image Immunochemistry system (Beckman Instruments, Ful-
lerton, CA), which has a minimum level of detection of 0.2
mg/liter. Serum levels of TNF were measured using a high-
sensitivity commercial enzyme-linked immunosorbent assay
(ELISA) with an alkaline phosphatase signal amplification
system for TNF (Quantikine High-Sensitivity ELISA, catalog
no. SSTA00D, lot no. 246936; R&D Systems, Minneapolis,
MN). Serum levels of IL-6 were measured using an ultrasen-
sitive ELISA kit (hIL-6 Ultra-Sensitivity ELISA, catalog no.
KHC0064, lot no. S070617D; BioSource, Nivelles, Belgium).
All measurements were carried out in accordance with the
manufacturers’ instructions and were implemented using the
microplate reader Opsys MR (Dynex, Alexandria, VA). The
minimum levels of detection were 0.038 pg/ml and 0.104
pg/ml for TNF and IL-6, respectively. The intra- and inter-
assay coefficients of variation for measurements of CRP, IL-6,
and TNF were 2.6%, 4.6%, and 5.3%, respectively, and 3.1%,
5.4, and 7.5%, respectively.
Statistical analysis. Basic statistical analysis of the data
obtained at each visit included analysis of the distribution
properties of the variables, as well as correlation analyses to
assess possible associations between each quantitative trait
(BMI and cytokine levels) and age and between traits. Specif-
ically, we examined the pairwise correlations between BMI and
levels of various cytokines within each year and between the
repeated measurements of the same variable (e.g., IL-6 at year
5 and IL-6 at year 8). Comparison of baseline measurements of
the continuous traits (BMI and cytokine levels) with followup
measurements was carried out using paired t-test and Fried-
man’s nonparametric repeated-measures comparison test, to
ensure that deviations from normality did not bias the para-
meter estimates, with nonindependence of the measurements
taken into account. Friedman’s test was also used to compare
the prevalence of RKOA among subjects at baseline (year 1)
and in the repeated examinations at years 10 and 15 of the
followup period. Cochran’s Q test for matched sets of frequen-
cies was also implemented, to ensure the reliability of the
observed significant differences.
For preliminary recognition of the potential predictor
variables for RKOA, the relationship between each variable
and RKOA was tested using a series of univariate analyses of
variance (ANOVAs). Specifically, we compared BMI and
cytokine levels by RKOA-affected status and at each visit
(years 1, 10, and 15). A similar procedure was then applied to
the combined data from 3 visits for each independent variable
separately, with simultaneous adjustment of the significance
level (P values) for repeated measurements. Specifically, we
Table 1. Basic descriptive statistics of the study sample by variable and visit*
Variable, visit
No. of
subjects Mean  SD
Median
(minimum–maximum)
Skewness†
R for
age‡ Mean (SEM) Ln_dst
Body mass index, kg/m
2
Year 1 1,002 25.585  4.251 24.850 (16.810–44.540) 1.201 (0.077) 0.066 0.102
Year 10 810 26.784  4.726 26.300 (17.000–59.400) 1.159 (0.085) 0.435 NS
Year 15 638 27.213  4.809 26.587 (16.344–46.991) 0.652 (0.096) 0.145 NS
Serum cytokine levels
hsCRP, mg/liter
Year 5 417 0.290  0.383 0.164 (3.850–0.020) 4.109 (0.120) 0.087 NS
Year 8 474 0.263  0.997 0.143 (21.200–0.012) 19.703 (0.112) 0.346 0.096
Year 15 319 0.300  0.404 0.203 (5.010–0.020) 6.607 (0.137) 0.026 NS
IL-6, pg/ml
Year 5 429 2.034  3.690 0.976 (24.889–0.185) 4.475 (0.118) 1.055 0.215
Year 8 473 3.002  4.319 1.560 (30.228–0.307) 3.654 (0.112) 0.870 0.139
Year 15 322 1.935  2.386 1.267 (20.028–0.162) 4.451 (0.136) 0.495 0.192
TNF, pg/ml
Year 5 430 8.367  17.333 3.375 (173.798–0.642) 5.379 (0.118) 0.904 0.151
Year 8 473 3.596  5.420 1.851 (48.061–0.672) 4.488 (0.112) 1.399 0.172
Year 15 322 1.496  0.848 1.192 (7.136–0.138) 2.065 (0.136) 0.305 NS
Age, years
Year 1 1,003 54.68  6.02 54.256 (44–68) – – –
Year 10 1,002 64.46  6.16 64.080 (53–78) – – –
Year 15 645 69.12  5.81 68.523 (60–82) – – –
*N S not significant (P  0.05); hsCRP  high-sensitivity C-reactive protein; IL-6  interleukin-6; TNF  tumor necrosis factor .
† Mean (SEM) values are the estimate of skewness of the original, nontransformed data, while the Ln_dst represents the results of the test for
normality of the distribution of the natural logarithm–transformed data (new estimate of skewness).
‡ Values are the root square multiple-determination correlation coefficient for age or, if significantly associated, age-squared.
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cytokine levels collected at years 5, 8, and 15 in individuals with
and those without RKOA. All of these statistical analyses were
conducted using the Statistica package, version 7 (StatSoft,
Minneapolis, MN).
The relative effect of the selected potential predictors
of the risk of development of RKOA was next examined using
logistic regression analysis with multiple predictor variables.
This was carried out in 2 stages. First, the dichotomous
variable for RKOA-affected status (affected [K/L grade 2]
versus unaffected [K/L grade 2]) at year 10 was analyzed by
standard logistic regression in a model that included quantita-
tive (continuous) variables (age and BMI at entry examination,
and cytokine levels measured at year 5) as predictors of risk
probability (as well as the odds ratio [OR] with 95% confi-
dence interval [95% CI]). In addition, longitudinal modeling of
the dichotomous responses was undertaken using models
implemented with the Stata statistical package (version 10;
StataCorp, College Station, TX). Similar to the above-
described logistic regression analysis, the longitudinal models
also tested the risk of RKOA as a function of the predictor
variables of interest. The data consisted of longitudinal dichot-
omous responses, with measurements at years 1, 10, and 15,
and data were nested in subjects, which meant that there was
dependence among the responses within the same subject.
In addition, a mixed-effects logistic model was used to
evaluate the relationship across time (at years 1, 10, and 15)
between the presence of RKOA (i.e., K/L grade 2) and the
continuous predictor variables, including age and BMI, which
were collected during the same years as the RKOA data, and
the levels of inflammatory cytokines, which were selected in
the univariate analyses and assayed at years 5, 8, and 15. This
Table 2. Comparison of the natural logarithm–transformed cytokine levels by radiographic knee osteoarthritis–affected status and visit*
Year 1 Year 10 Year 15
Unaffected Affected Unaffected Affected Unaffected Affected
IL-6
Year 5
P versus unaffected 0.0002 0.0002 0.003
No. of subjects 370 57 257 169 154 165
Mean  SD pg/ml 0.05  0.88 0.55  1.11 0.02  0.88 0.32  0.97 0.03  0.83 0.27  0.98
Year 8
P versus unaffected 0.032† 0.037† 0.264
No. of subjects 412 58 290 180 176 176
Mean  SD pg/ml 0.56  0.91 0.83  0.79 0.52  0.94 0.70  0.82 0.48  0.95 0.59  0.86
Year 15
P versus unaffected 0.127 0.026† 0.011†
No. of subjects 283 39 200 122 156 156
Mean  SD pg/ml 0.27  0.78 0.48  0.83 0.22  0.77 0.42  0.81 0.16  0.77 0.39  0.78
TNF
Year 5
P versus unaffected 0.832 0.285 0.3775
No. of subjects 371 56 258 169 155 165
Mean  SD pg/ml 1.37  1.06 1.41  1.05 1.33  1.06 1.45  1.06 1.34  1.06 1.44  1.13
Year 8
P versus unaffected 0.0007† 0.375 0.597
No. of subjects 412 58 290 180 176 176
Mean  SD pg/ml 0.79  0.75 1.16  0.87 0.81  0.78 0.88  0.76 0.82  0.81 0.86  0.75
Year 15
P versus unaffected 0.458 0.834 0.656
No. of subjects 283 39 200 122 157 156
Mean  SD pg/ml 0.28  0.50 0.22  0.44 0.27  0.50 0.28  0.47 0.29  0.51 0.26  0.47
CRP
Year 5
P versus unaffected 0.006† 0.010† 0.096
No. of subjects 358 56 248 166 146 163
Mean  SD mg/liter 1.82  1.08 1.45  1.15 1.93  1.02 1.65  1.15 1.94  1.01 1.74  1.14
Year 8
P versus unaffected 0.051† 0.555 0.851
No. of subjects 409 62 287 184 174 174
Mean  SD mg/liter 2.01  0.99 1.75  0.94 2.00  1.02 1.94  0.94 1.99  1.02 1.97  0.93
Year 15
P versus unaffected 0.377 0.026† 0.001†
No. of subjects 280 39 198 121 154 155
Mean  SD mg/liter 1.70  0.99 1.55  0.93 1.77  0.97 1.52  0.98 1.86  0.99 1.51  0.94
* IL-6  interleukin-6; TNF  tumor necrosis factor ; CRP  C-reactive protein.
† P  0.05 versus unaffected, by analysis of variance.
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dence both in the RKOA data and in the predictor variables
(for further details, see ref. 23).
RESULTS
Descriptive statistics. The sample characteristics,
including the sample sizes for each trait determined at
each visit as well as the levels of circulating cytokines and
BMI, are provided in Table 1. Not all individuals whose
radiographic and BMI data were available could be
assayed for cytokine levels. Initial analyses revealed that
the data on cytokine levels were not distributed nor-
mally, in that values showed significant skewness to the
right. These data were therefore subjected to adjustment
using natural logarithm transformation, which improved
the data distribution substantially (Table 1).
Nine hundred eight individuals with complete
data on the K/L grade of RKOA were available at the
entry examination, while 2 subjects were lost to followup
by year 10, and 293 subjects were lost to followup by year
15. The main reasons for the loss to followup by year 15
included mortality unrelated to RKOA (99 individuals),
withdrew from the study (85 individuals), moved to a
different address (75 individuals), and unknown reasons
(36 individuals). At baseline, 15.3% of subjects reported
having knee pain. During followup, the prevalence of
RKOA in either knee increased from 14.7% to 37.4% by
year 10, and to 48.7% by year 15. The observed change
in RKOA prevalence over the 3 visits was highly statis-
tically significant (
2  330.1, 2 df; P  0.00001 versus
baseline, by Friedman’s test). The prevalence of RKOA
in each knee, as assessed by K/L grade, was comparable,
with a slight excess in the right knee compared with the
left knee, with prevalences at baseline, year 10, and year
15 of 11.0% versus 8.8%, 30.9% versus 25.6%, and
42.1% versus 36.3%, respectively. These differences in
RKOA prevalence between knees appeared to be statis-
tically significant (P  0.042–0.001 at each visit sepa-
rately, by Friedman’s test and, especially, by Cochran’s
Q test; P  0.00001 for the 3 visits combined).
Circulating levels of each of the 3 cytokines were
within the ranges expected for a normal population. The
correlations of the circulating cytokine levels with age
were all low and, in some instances, statistically nonsig-
nificant (Table 1). There were no significant correlations
between the individual measurements of TNF at dif-
ferent visits; however, mean TNF levels clearly de-
creased from year 5 to year 15 (P  0.001) (Table 1).
The mean values for CRP and IL-6 showed no clear
trend with each followup visit. When individual serum
concentrations of CRP and IL-6 were compared be-
tween the years, we found low correlations between the
IL-6 levels (r  0.22–0.24, P  0.01) and moderate
correlations between the CRP concentrations (r  0.46–
0.48, P  0.001). Adjusted for age, IL-6 levels correlated
significantly with CRP concentrations in all possible
pairwise comparisons, with correlations ranging from
0.22 to 0.48 (P  0.01). Of note, there was very little bias
resulting from withdrawal from the study, since age, IL-6
levels, and RKOA prevalence rates among those who
withdrew were all comparable with the values in the total
sample, specifically for RKOA prevalence at baseline
(P  0.26) and for the total assayed level of IL-6 at year
5( P  0.94).
Association between RKOA status and circulat-
ing biomarker levels. The mean age, BMI measure-
ments, and IL-6 levels were consistently higher in
RKOA-affected individuals than in unaffected individu-
als, as determined by univariate ANOVAs (Table 2).
When the respective data from the 3 visits (for BMI and
IL-6 measurements separately) were combined and the
implemented ANOVAs were corrected for repeated
measurements, the differences between RKOA-affected
and unaffected individuals were significant (P  0.001)
for both variables. In particular, the circulating levels of
IL-6 were substantially higher in individuals with severe
RKOA (defined as a K/L grade 2 in either or both
knees) (Figure 1). CRP levels were also consistently
higher in affected individuals, although the differences
in CRP levels between affected and unaffected individ-
Figure 1. Mean interleukin-6 (IL-6) levels standardized for visit-
specific mean and variance (IL6 STD) in 3 radiographic knee osteo-
arthritis (RKOA) categories: 1  unaffected (Kellgren/Lawrence
[K/L] grade 2), 2  initial stage of RKOA (K/L grade 2), and 3 
severe RKOA (K/L grade 2). Bars show the 95% confidence
intervals. The unadjusted sample sizes were 931, 174, and 101 individ-
uals in RKOA categories 1, 2, and 3, respectively.
IL-6 IN RADIOGRAPHIC KNEE OA 2041uals did not reach statistical significance in 4 of 9
comparisons. However, when the data from the 3 visits
were combined and corrected for repeated measure-
ments, there was a significant trend toward higher levels
of CRP in affected individuals (P  0.002 versus unaf-
fected).
BMI, IL-6 levels, and CRP levels, as well as the
mean age per time point, were then examined by multi-
ple logistic regression analysis. As shown in Table 3, age
and BMI at baseline and IL-6 levels at year 5 were
retained in the model as significant predictors of subse-
quent RKOA at year 10, suggesting that individuals were
more likely to be diagnosed as having RKOA if they had
a higher BMI at baseline (OR 1.115, 95% CI 1.051–
1.184 per kg/m
2) and increased IL-6 levels (logarithm-
transformed) at year 5 (OR 1.340, 95% CI 1.064–1.687
pg/ml).
Finally, longitudinal modeling of repeated mea-
surements using mixed-effects logistic regression analy-
sis confirmed the results obtained by multiple logistic
regression (Table 4). In the longitudinal analysis, for the
sake of simplicity, determinations of RKOA, age, and
BMI at years 1, 10, and 15 and the cytokine measure-
ments at years 5, 8, and 15 were designated visits 1, 2,
and 3, respectively. Results were consistent for diverse
comparisons of the visits, e.g., visit 1 compared with visit
2, visit 1 compared with visit 3, or all 3 visits compared.
The results showed that older age, higher BMI, and
increased IL-6 levels were all significant independent
predictors of RKOA status, while CRP levels did not
make a significant independent contribution.
Figure 2 shows the predicted risk of RKOA at
ages 50, 60, and 70 years as a function of BMI and IL-6
levels; i.e., we estimated the probability of the individual
having RKOA according to 3 specific categories of BMI
(1  21–30 kg/m
2,2 31–40 kg/m
2, and 3  41–50
kg/m
2) and according to quartiles of logarithm-
transformed mean IL-6 measurements. The interplay
observed between IL-6 levels and BMI indicated that at
age 50 years, the effect of both BMI and IL-6 levels
appeared in only very-obese individuals (those in BMI
category 3) (Figure 2A). At age 70 years, the effect was
evident in less-obese individuals (those with a BMI of
30 kg/m
2) (Figure 2C). The effect of IL-6 levels was
seen particularly well in this latter group (Figure 2C)
and also in individuals at age 50 years whose BMI was
50 kg/m
2 (Figure 2A). The risk of RKOA clearly
increased with increasing IL-6 levels in individuals at age
60 years whose BMI was 40 kg/m
2 (Figure 2B).
When the effects of IL-6 levels alone were as-
sessed, the comparison of the quartiles showed that the
likelihood of being diagnosed as having RKOA in
individuals with IL-6 levels in the fourth quartile (versus
the first quartile) was 2.74 (95% CI 1.94–3.87; P 
0.001) when only individuals with a K/L grade 2 were
considered. In individuals with severe RKOA (K/L
Table 3. Multiple logistic regression analysis of significant predictors of radiographic knee osteoarthritis at year 10*
Effect Estimate
Standard
error
Odds ratio
(unit change) 95% CI P
Intercept 7.520 1.254 – 4.5  10
9
Age 0.076 0.018 1.079 1.041–1.119 3.93  10
5
BMI 0.109 0.109 1.115 1.051–1.184 0.0003
Ln_IL-6 0.293 0.117 1.340 1.064–1.687 0.0129
* Independent variables included age and body mass index (BMI) at baseline and C-reactive protein and interleukin-6 (IL-6)
levels at year 5. Only significant results are shown. 95% CI  95% confidence interval; Ln_IL-6  natural logarithm–
transformed IL-6 levels.
Table 4. Mixed-effects logistic regression analysis of the significant predictors of radiographic knee osteoarthritis from repeated measurements at
years 1, 10, and 15*
Effect
Visits 1 and 2 Visits 1 and 3 Visits 1, 2, and 3
Estimate Standard error P Estimate Standard error P Estimate Standard error P
Intercept 28.988 7.140 0.001 55.797 14.114 0.001 84.624 13.874 0.001
Age 0.289 0.076 0.001 0.518 0.137 0.001 0.917 0.163 0.001
BMI 0.325 0.912 0.001 0.727 0.211 0.001 0.765 0.165 0.001
Ln_IL-6 0.137 0.063 0.028 1.327 0.625 0.034 1.107 0.490 0.024
* Independent variables included age and BMI at years 1, 10, and 15 and C-reactive protein and IL-6 levels at years 5, 8, and 15 (designated visits
1, 2, and 3, respectively). Only significant results are shown. See Table 3 for definitions.
2042 LIVSHITS ET ALgrade 2 in either or both knees), the OR for those in
the fourth quartile of IL-6 levels (versus the first quar-
tile) reached 3.59 (95% CI 1.93–6.68; P  0.001).
DISCUSSION
The prevalence of RKOA in this population
sample of women whose data were obtained from gen-
eral practice registers in the UK increased during the 15
years of followup, from 14.7% to 48.7%. We also noted
the higher prevalence of OA in the right knee (versus
the left), suggesting involvement of mechanical factors
in RKOA etiologic development. The novel finding of
this study was a consistent association of IL-6 circulating
levels with the prevalence and incidence of RKOA as
assessed by K/L grade. IL-6 levels were consistently
found to be associated with the RKOA prevalence in the
specific year and when the 3 visits were combined. Two
other variables that were consistent predictors of the
appearance of RKOA were age and BMI (Tables 3
and 4).
Although the evidence for an association with
serum TNF levels was negligible, CRP levels were also
significantly associated with RKOA when considered
separately (Table 2). However, the effect of CRP disap-
peared after adjustment for age and IL-6 levels in
multivariate analysis (Tables 3 and 4), likely because the
CRP concentration and the levels of IL-6 are related
biologically. In our study, the serum concentrations of
CRP and IL-6 showed a significant correlation, which
varied between 0.22 and 0.48 (P  0.001), depending on
the year of the visit. CRP levels showed very low,
nonsignificant correlations with age. This may account
for our earlier findings of a significant predictive effect
of CRP in the same sample (16). In the present sample,
when the IL-6 effect was considered alone, it showed a
highly significant association with RKOA (P  0.001).
As a result, the prevalence comparison between the first
and fourth quartiles of IL-6 levels yielded an OR of 2.74
(95% CI 1.94–3.87; P  0.001) for those with K/L grade
2 knees, and an OR of 3.59 (95% CI 1.93–6.68; P 
0.001) when only those with severe RKOA (K/L grade
2) were considered.
A growing body of evidence suggests that devel-
opment of OA, even at the early stages, is often accom-
panied by inflammation (24). This is consistent with the
findings from epidemiologic studies in which the severity
and progression of tibiofemoral cartilage damage were
observed to be more common and severe in patients
having reactive and inflamed synovial fluid (25). More-
over, elevated levels of cytokines such as IL-1 and
TNF, both of which are regulators of inflammation, are
found in the disease process, although their precise cell
of origin is not clear (17,26). Increased levels of CRP
have been associated with the prevalence and progres-
Figure 2. Risk probability for radiographic knee osteoarthritis
(Kellgren/Lawrence grade 2) in the Chingford Study at ages 50 years
(A), 60 years (B), and 70 years (C) as a function of body mass index
(BMI) and circulating levels of interleukin-6 (IL-6). Values are the
mixed-effects logistic model parameter estimates (see Table 4) for 3
categories of BMI (1  21–30 kg/m
2,2 31–40 kg/m
2, and 3  41–50
kg/m
2) and for quartiles of IL-6 distribution (S1– S4). The values of the
boundary at the 25th, 50th (median), and 75th percentiles of IL-6
levels were 0.767 pg/ml, 1.235 pg/ml, and 2.310 pg/ml, respectively, with
corresponding minimum and maximum values of 0.162 pg/ml and
30.228 pg/ml, respectively, at the tails of the distribution. All IL-6 data
were logarithm-transformed.
IL-6 IN RADIOGRAPHIC KNEE OA 2043sion of knee and hip OA in several studies (16,18,27),
although in other studies, this association became non-
significant after adjustment for BMI (19). Of note,
however, to our knowledge, there is no published study
examining the association between OA and circulating
IL-6 levels. Thus, the present study is the first to assess
this association.
One potential source of these inflammatory cy-
tokines is adipose tissue, which accompanies obesity (28)
and which is known to be associated with high levels of
biomarkers of inflammation, including IL-6 (7,29). In
the study by Das (29), the results suggest that synthesis
of TNF (and leptin) in adipose tissue could induce the
production of IL-6 and the acute-phase reactant CRP.
Increased levels of these cytokines may, in turn, contrib-
ute to the development of OA. Our data support this
observation. In our study, we observed significantly
higher BMI values in individuals affected with RKOA.
Moreover, the correlation between BMI and RKOA was
found not only with the weight-bearing knee joints but
also with hand OA in the present sample (results not
shown). The link between obesity and hand OA was
noted some time ago (e.g., see ref. 30). Although the
mechanism remains to be debated, one of the most
popular theories is that fat tissue causes systemic release
of proinflammatory cytokines. Circulating IL-6, as men-
tioned above, is known to stimulate CRP production by
the liver. Indeed, we observed consistent correlations
between the CRP levels and IL-6 levels, and significantly
higher CRP levels in RKOA-affected individuals.
There are several limitations to this study. First,
there is a discrepancy in the timing of the study assess-
ments of RKOA and the cytokine assays (Table 1).
Serum samples were not available at baseline when the
first set of radiographs was obtained. Thus, it is not
known how many individuals had RKOA at year 5 (when
the first serum samples were assayed). Likewise, the
number of subjects having elevated IL-6 levels at base-
line, when the first radiographic examination was con-
ducted, is not known. This was the main reason for
testing the association between the cytokine levels at
year 5 with RKOA at year 10.
The second limitation is that inflammatory cyto-
kines were measured in the circulation and not in
synovial fluid. It is possible that serum cytokines could
originate from a different tissue. In addition, the de-
creasing sample size with each followup visit, albeit
inevitable in a longitudinal study of this kind, did
contribute to a loss of statistical power. We found,
however, no evidence of a systematic bias resulting from
the loss of baseline subjects at followup. First, only a
relatively small proportion of the sample was lost during
the followup period. Second, IL-6 levels and OA prev-
alence rates at the baseline examination did not differ
between those who subsequently dropped out and the
total group.
The effect of limited sample size was pronounced
when multivariate analyses were undertaken, since the
small sample numbers at baseline would not allow us to
specifically examine progressive disease. However, we
believe that incidence and progression may be inter-
changeable in this kind of study. For example, since we
defined RKOA as a K/L grade 2 in either knee, those
with a K/L grade 1 at baseline whose disease then
progressed would be considered an incident case, al-
though really they should be considered “progressors.”
Indeed, when we compared IL-6 levels according to K/L
grade (unaffected  K/L grade 2, minor RKOA  K/L
grade  2, and severe RKOA  K/L grade 2), a
consistent association of continuous increases in these
parameters was observed (Figure 1), which was consis-
tent with the ORs for RKOA by quartiles of IL-6 levels.
Similarly, if we had used magnetic resonance imaging or
another more sensitive measure of disease, then most
incident cases would probably be those with minor OA
detectable at baseline. Clearly, the study would have
benefited from current radiologic standards and tech-
niques for the knee, although any misclassification due
to the extended knee position would have acted to
obscure the results.
It is also important to note that this study did not
examine the effect of OA comorbidity in the other
joints. This would lead to a much more complex analysis
of the data, which was beyond the scope of this study.
A further, minor limitation is that the study was
undertaken using data only from female subjects. OA is
increasingly recognized to be site- and sex-specific, and
therefore the present results may not be directly extrap-
olated to men. There is little evidence, however, to
suggest that cytokine expression differs significantly
between the sexes.
In conclusion, the present findings suggest that a
higher BMI and increased circulating levels of IL-6 are
associated with the development of RKOA. IL-6 is
therefore a potential new biomarker for OA develop-
ment and may provide useful information in the predic-
tion of disease outcome. Moreover, highlighting the
potential key role of IL-6 in the disease process may
lead to studies of IL-6 blockade as a therapeutic strategy
in OA.
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